Misleading claims

The effects of concentration or dilution of the active ingredient on the activity of a disinfectant are of paramount importance. Failure to be aware of these changes in activity is responsible for many misleading claims concerning the properties of a disinfectant. 

It should also be noted that comparison of quenching efficiency of conjugated polymers with small-molecule fluorophores is complicated and oversimplification can lead to misleading claims of exceptional sensitivity enhancements. In their 2007 review, Swager and co-workers discuss cases where the charge state of the small molecule used for comparison differed fundamentally from the polymer and exceptional quenching efficiencies were inappropriately attributed to super-quenching alone [3], In addition, a polymer will create a different local... 

The benefits of the DSHEA to the manufacturers of natural products is obvious. They can claim a variety of health benefits for their products in very general terms that may sound to consumers like health claims but usually are not. They also can (although they are unlikely to attempt to) sell products that do not contain the chemicals listed on the label, are not safe for human consumption, or are not effective at treating the conditions for which they are recommended. In some ways, this situation sounds similar to the conditions that existed at the beginning of the 20th century, when the FDA was created to deal with the false and misleading claims of patent medicine suppliers. 

Discontinuation Problems Further controversy has surrounded misleading claims in the lay media that SSRls have addictive properties. These centre around reports of patients suffering symptoms when trying to discontinue medication. As with the benzodiazepines, these symptoms may be a recurrence of the premorbid anxiety, although rebound anxiety has not been clearly demonstrated. Self-limiting symptoms associated with SSRl withdrawal have been widely reported (Haddad 1998), and are generally described as the SSRl discontinuation syndrome (Table 4). The most frequently occurring symptoms are dizziness, nausea and headache. 

Theodore Roosevelt, Republican president of the United States from 1901 to 1909. Concerned about the impurity and misleading claims of patent medicines, he supported government efforts to improve the safety of drug use with the passage of the 1906 Pure Food and Drug Act. The legislation represented a modest first step but was followed by stronger efforts in decades to follow. 

Celebrex New Ad, with Questionable Claims. Consumer Reports 72, no. 8 (August 2007) 52-53. This article illustrates the kind of misleading claims that often appear in DTC drug ads. It examines claims made in an ad that Celebrex poses no more risks than other prescription pain relievers. 

However, in pretending to offer mathematical solutions of chemical problems, much greater significance became attached to the results obtained than the numerous assumptions and simplifications required could justify. The often exaggerated, if not misleading, claims have discouraged the development of empirical, semi-quantitative theories which alone have been responsible for the development of theoretical chemistry. 

It is important that claims made for medicines do not mislead either intentionally or unintentionally. Therefore, it is important to consider whether the information presented in advertising and promotion can be misconstrued in any way. The way that graphs are presented and statistics are used in promotional items are common causes of false or misleading claims. These are therefore looked at in more detail here. 

This misleading claim is made from time to time by those associated with the Cochrane Collaboration (CC). For example, Jadad et cd. (2000) carried out a review of 50 metaanalyses in asthma and concluded that most reviews published in peer-reviewed journals or funded by Industry have serious methodological flaws that limit their value to guide decisions. Cochrane reviews are more rigorous and better reported than those... 

Narayan, R. (2010) Misleading Claims and Misuse of Standards Continues to Proliferate in the Nascent BioPlastics Industry Space. BioPlastics Magazine (Jan.)... 

The term bioplastics covers both the biobased and biodegradable-compostable class of plastics. In this chapter we will review the principles and value proposition for bioplastics, the underlying scientific basis, the misuse and misleading claims in the marketplace, and the proper use of international standards. 

---